These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28458336)

  • 1. Alfacalcidol Increases the Therapeutic Efficacy of Ibandronate on Bone Mineral Density in Japanese Women with Primary Osteoporosis.
    Nakamura Y; Suzuki T; Kamimura M; Ikegami S; Uchiyama S; Kato H
    Tohoku J Exp Med; 2017 Apr; 241(4):319-326. PubMed ID: 28458336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eldecalcitol, in Combination with Bisphosphonate, Is Effective for Treatment of Japanese Osteoporotic Patients.
    Mukaiyama K; Uchiyama S; Nakamura Y; Ikegami S; Taguchi A; Kamimura M; Kato H
    Tohoku J Exp Med; 2015 Dec; 237(4):339-43. PubMed ID: 26639092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment.
    Iba K; Sonoda T; Takada J; Dohke T; Yamashita T
    J Bone Miner Metab; 2017 Mar; 35(2):171-176. PubMed ID: 26832388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis.
    Uehara M; Nakamura Y; Suzuki T; Nakano M; Takahashi J
    J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study.
    Soen S; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Ito M; Nakano T; Hagino H; Hirakawa A; Matsumoto T
    J Bone Miner Metab; 2020 Jul; 38(4):511-521. PubMed ID: 31970477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study.
    Senn C; Günther B; Popp AW; Perrelet R; Hans D; Lippuner K
    Osteoporos Int; 2014 Jul; 25(7):1945-51. PubMed ID: 24760244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.
    Hakala M; Kröger H; Valleala H; Hienonen-Kempas T; Lehtonen-Veromaa M; Heikkinen J; Tuomiranta T; Hannonen P; Paimela L;
    Scand J Rheumatol; 2012 Aug; 41(4):260-6. PubMed ID: 22803768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous treatment with ibandronate normalizes bone matrix mineralization and reduces cortical porosity after two years in male osteoporosis: a paired biopsy study.
    Misof BM; Patsch JM; Roschger P; Muschitz C; Gamsjaeger S; Paschalis EP; Prokop E; Klaushofer K; Pietschmann P; Resch H
    J Bone Miner Res; 2014 Feb; 29(2):440-9. PubMed ID: 23832525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of monthly intravenous ibandronate on the low responders to oral bisphosphonate: the MOVEMENT study.
    Hagino H; Sakai A; Ikeda S; Imanishi Y; Tsurukami H; Nakajo S; Miyakoshi N
    J Bone Miner Metab; 2019 Nov; 37(6):1013-1023. PubMed ID: 31098670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures.
    Iwamoto J; Sato Y; Uzawa M; Takeda T; Matsumoto H
    Yonsei Med J; 2009 Aug; 50(4):474-81. PubMed ID: 19718394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.
    Li M; Xing XP; Zhang ZL; Liu JL; Zhang ZL; Liu DG; Xia WB; Meng XW
    J Bone Miner Metab; 2010 May; 28(3):299-305. PubMed ID: 19855926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibandronate treatment reverses glucocorticoid-induced loss of bone mineral density and strength in minipigs.
    Glüer CC; Scholz-Ahrens KE; Helfenstein A; Delling G; Timm W; Açil Y; Barkmann R; Hassenpflug J; Stampa B; Bauss F; Schrezenmeir J
    Bone; 2007 Mar; 40(3):645-55. PubMed ID: 17174621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences of therapeutic effects on regional bone mineral density and markers of bone mineral metabolism between alendronate and alfacalcidol in Japanese osteoporotic women.
    Takata S; Abbaspour A; Yonezu H; Yasui N
    J Med Invest; 2007 Feb; 54(1-2):35-40. PubMed ID: 17380012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of monthly ibandronate in men with low bone density.
    Orwoll ES; Binkley NC; Lewiecki EM; Gruntmanis U; Fries MA; Dasic G
    Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D and Calcium Addition during Denosumab Therapy over a Period of Four Years Significantly Improves Lumbar Bone Mineral Density in Japanese Osteoporosis Patients.
    Suzuki T; Nakamura Y; Kato H
    Nutrients; 2018 Feb; 10(3):. PubMed ID: 29495518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of combined treatment with ibandronate and pulsed electromagnetic field on ovariectomy-induced osteoporosis in rats.
    Zhou J; Liao Y; Xie H; Liao Y; Zeng Y; Li N; Sun G; Wu Q; Zhou G
    Bioelectromagnetics; 2017 Jan; 38(1):31-40. PubMed ID: 27711964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis.
    Ma Z; Li Y; Zhou M; Huang K; Hu H; Liu X; Xu X
    PLoS One; 2016; 11(3):e0150203. PubMed ID: 26930292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
    Tan W; Sun J; Zhou L; Li Y; Wu X
    J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.